PK and PD as predictors of clinical effect. 2 PKPD workshop at AGAH/Club Phase I drug action – the interaction of the drug molecule at the binding site.
2/5/2010 – 1:00ameSlide – P6617 – MedImmune 8 x 4 Poster Template Objectives: Moxetumomab pasudotox (CAT-8015) is a recombinant immunotoxin composed of.
PK and PD as predictors of clinical effect
